Purpose The current study presents a Bayesian approach to non-compartmental analysis (NCA), which provides the accurate and precise estimate of AUC 0 ∞ and any AUC 0 ∞ -based NCA parameter or derivation.
The terminal elimination rate constant μ j
Mean of the log-transformed concentrations at the jth time point μ * j
The vector (μ pl,j μ br,j )
T Σj Within-animal precision variance-covariance matrix of concentrations at time j σ j Variance or covariance of the plasma and brain concentrations at the j th time point σ*
Standard deviation of the log-normal distribution of concentrations at the last three time points of a concentration-time profile α
The intercept for the terminal phase regression β
The slope for the terminal phase regression
INTRODUCTION
In preclinical studies, the partition coefficient or so-called equilibrium-distribution coefficient, expressed by the ratio of tissue-to-plasma area under the concentration curve (AUC) from time zero to infinity ( , where the subscript br denotes the brain or any other tissue under investigation and pl denotes the plasma), has been widely used as a key metric to reflect the tissue distribution of a compound (1, 2) . For instance, when the compound under investigation is a substrate of the blood-brain barrier (BBB) efflux transporter system, it is becoming increasingly important to characterize the brain-toplasma partition coefficient in order to assess the brain penetration of the compound in drug discovery (3) . The ratio of AUC from time zero to infinity (AUC 0 ∞ ) is also of primary importance in bioequivalence studies. In addition, the drug targeting index (DTI, the ratio of AUC 0 ∞ at target and systemic site following administration into and sampling from both sites) is widely used in regional drug delivery research (4, 5) . Nevertheless, to determine the true tissue-to-plasma AUC 0 ∞ ratio or the true DTI is usually not straightforward due to experimental error and the variation between animals. In order to obtain the statistical inference of AUC 0 ∞ , it is ideal to perform intensive serial sampling in each individual animal. However, the withdrawal of a sufficient number of blood samples from individual rodents for AUC determination is restricted due to technical and financial reasons. A common scenario in preclinical pharmacokinetic studies with small animals is the use of a sparse sampling approach with few time points, in which each animal is not sampled at all time points. Typically, in a serial sacrifice design (or so-called "destructive sampling"), only one sample per animal is available (6) . In this experimental scenario, more challenges arise in the estimation of AUC 0 ∞ variance than in the intensive sampling design. Accordingly, it is even more difficult to make the statistical inference of the partition coefficient and DTI. Under serial sacrifice design, there is theoretically no correlation in drug concentrations between different time points, however, the correlation between the tissue and the plasma concentrations within an animal cannot be ignored (see Fig. 1 ). The occurrence of plasma and tissue correlation at each time point further complicates the estimation of the variability around AU C ∞ 0;br AU C ∞ 0;pl . As far as we know, no conventional method provides solutions with the correlation taken into account.
AU C
In recent years, Bayesian approaches have been widely applied to clinical trials (7-10) and pharmacokinetic (PK) & pharmacodynamic studies (11, 12) . Unlike the frequentist view that the conclusions made from the current work are independent of prior work, the Bayesian approach acknowledges that parameters are random variables that follow an unknown distribution instead of fixed constants, and that existing knowledge could be incorporated into the analysis as an informative prior, if any. The priors in Bayesian statistics reflect the investigator's beliefs in specific parameters before the beginning of the study and the Bayesian approach allows estimation of a parameter of interest by incorporating existing knowledge. When there is little or no prior information available, a non-informative prior can be used. The posterior distribution of a certain parameter is derived via the simulation-based method, with the knowledge of prior distribution of the parameter estimates and the actual data. Bayesian methods implement a simulation-based approach to obtain the point estimate of posterior expectation and any quantile of interest, and it is applicable for sparse sampling data. The most pertinent advantage of this proposed approach is the ability in estimating the uncertainty of any noncompartmental analysis (NCA) parameter through the posterior samplings of the mean concentration at each time point.
The current study presents a novel Bayesian NCA approach using the BUGS (Bayesian inference Using Gibbs Sampling) software, which provides the posterior distributions of not only the AUC 0 ∞ but also of the AUC 0 ∞ ratio and the DTI. Since no prior information was used in our study, noninformative or vague prior distributions were assumed for all model parameters.
THEORY
Bailer's method was first proposed and has been most commonly used to estimate the AUC from time zero to the last sampling time point (AUC 0 t ) based on the linear trapezoidal rule. The corresponding variance of the estimated AUC 0 t was calculated based on the linear relation of normally distributed sample errors of concentration at each time point (13) . Bailer-Satterwaite method improves the accuracy of the population variance estimation by the Bailer's method when sample sizes are not adequately large, and expands the Bailer's method for AUC confidence intervals in sparse sampling (14) . However, in a study under serial sacrifice design, Bailer-Satterwaite method was still unable to obtain the variance of the AUC 0 ∞ , as described as follows:
where C t represents the concentration at the last sampling time point, and λ z denotes the terminal elimination rate constant that can be estimated by the linear regression from the logarithm of concentrations at the last at lease three sampling points. Now the question at hand is how to estimate the variance of AUC 0 ∞ , and further conduct contrasts between different AUC 0 ∞ s. Yuan extends the Bailer's method to infinite time and construct confidence intervals for AUC 0 ∞ (15). Yuan's method proposed the following approximation for the variability of AUC 0 ∞ by assuming that all the samples are independent and that λ z is known and identical for all tested animals:
where SD(·) denotes the standard deviation; SE j is the standard error of C j , the concentration at the j th time point; SE 0 denotes the standard error of the concentrations at time zero; the subscript m is the total number of sampling time points; and the λ z represents the terminal rate constant. Yuan also pointed out that because of the covariance between the mean concentration at the j th time point and λ z , Eq. 2 underestimated the variation of AUC 0 ∞ . It was proposed that one more term should be added to the variance of AUC 0 ∞ if λ z is estimated from an independent study. However, it is usually hard to fulfill in practice. Thus, Yuan's method also has some inherent limitations because of its assumptions. Moreover, one problem not addressed in Yuan's method is the estimation of the variance of partition coefficient, and therefore the variance of DTI, which requires more strict statistical assumptions and complicated mathematical computation. Alternatively, resampling-based approaches have become an option to obtain the non-parametric confidence intervals of AUC 0 ∞ or AUC 0 ∞ via bootstrapping and jackknifing (6, (16) (17) (18) (19) .
However, the sample size for resampling is an important issue to consider when using these methods (16, 20) . The coverage rate of resampling-based approaches is a concern, especially for bootstrap. The biggest disadvantage of resampling-based approaches is that it provides no guarantees on general finitesample and tends to be overly optimistic, which makes its application on sparse sampling designs questionable (16) .
Here in this paper, we proposed a Bayesian approach to estimate the variance of AUC 0 ∞ and AUC 0 ∞ -based parameters such as partition coefficient and DTI. The Bayesian approach is based on the conventional method of AUC 0 ∞ calculation (Eq. 1). The main difference from conventional methods is that the model based-mean concentrations at the different time points are used for AUC calculation. The Bayesian NCA approach presented here includes the following statistical assumptions:
Likelihood
Assume the plasma and the tissue (e.g., the brain, in this paper) concentration measurements were obtained on the i th animal at the j th sampling time as C * i j (or C pl,ij and C br,ij , respectively). For each sampling time point, there were n animals for sample collection. Log-normality was assumed for the individual-
Or explicitly,
where MVN (·,·) denotes a bivariate normal distribution. μ * j is a vector with two components (μ pl,j and μ br,j ), representing means of the log-transformed plasma and brain concentrations (C pl,ij and C br,ij ), respectively. Σj is the within-animal precision matrix of concentrations at the j th time point; and σ j denotes the variance of the plasma or brain concentrations or covariance of the plasma and brain concentrations at the j th time point. With the precision matrix, the correlation between C pl,ij and C br,ij was taken into account in model setting, which could improve the precision of estimate.
Prior Specification
A non-informative (vague) prior distribution model was constructed in the absence of prior knowledge about model parameters. The prior distributions of μ pl,j and μ br,j were assumed as uniform distributions (Unif) in a wide range, for instance,
where a is a large positive number indicating vague priors. Typically, prior distributions of parameters are specified for mathematical convenience to compute posteriors. Thus, the inverse of the variance-covariance matrix (Σ −1 ), or so-called precision matrix, was set as a 2-dimensional Wishart distribution, a probability distribution of random nonnegative-definite symmetric matrices. Accordingly, the variance-covariance matrix of concentrations at the j th time point (Σj ) follows an Inverse-Wishart distribution as follow,
where R is a two-dimensional scale matrix; d is the degree of freedom. By setting small values as the diagonal elements of R (e.g., 0.01) and the degree of freedom (e.g., 2), vague priors for the correlation parameters were used.
The two Markov chain Monte Carlo (MCMC) chains were generated by OpenBUGS version 3.2.2 (www.mrc-bsu.cam. ac.uk/bugs/welcome.shtml) to obtain the posterior samples. To ensure that stationary distributions for the parameters were achieved, the first 10,000 samples for each chain were discarded (termed "burn-in period") and the following 20,000 samples were retained for inference. Sampler convergence was assessed by visual inspection of the trace plot (i.e. , plotting the draw of the parameter against iteration number for each Markov chain), autocorrelation, and the GelmanRubin diagnostic for each parameter. The median of the posterior samples (the 50th percentile) and 95% credible interval (C. I., the range from the 2.5th to 97.5th percentile) were summarized.
The Calculation of AUC and Terminal Elimination Rate Constant
Parameters such as AUC and the brain-to-plasma AUC ratio were estimated within a Bayesian framework using R-package "BRugs" version 0.8-1 (21) . In the current study, even though we could incorporate prior information into the analysis, we used non-informative priors throughout. Both brain and plasma AUC 0 t were calculated from model-based mean concentrations by the trapezoidal rule. Equation 1 shows that AUC 0 ∞ is the sum of AUC 0 t and C t /λ z . Thus it was desirable to determine the terminal elimination rate constant λ z to calculate AUC from the last sampling time to infinity.
By assuming a first-order elimination process at terminal phase including the last three time points (t j* ) in the current study, the terminal elimination rate constant λ z can be estimated using linear regression on the naturally-logtransformed concentrations at the last three time points (C j* ), which yields a log-normal likelihood as shown below.
where N(α -β ·t j * ,σ *2
) denotes a normal distribution with the mean (α-β ·t j* ) and standard deviation σ * ; α is the intercept term and the slope term β defines the terminal elimination rate constant λ z . The priors for α and β were assumed to follow the following uniform distributions:
where b and c were large positive values indicating vague priors. Similar to the variance-covariance matrix Σj as described in the "Theory" section, an inverse-gamma prior was specified for σ * 2 , which is also the standard conjugate prior for the normal variance for computing convenience. The superparameters of k and θ in the inverse-gamma distribution (Inverse-Gamma (k, θ)) were set to be 0.01 to ensure "vague" priors: 
SIMULATION
In order to examine the precision and coverage by Bayesian approach in estimation of the AUC 0 ∞ and the tissue-to-plasma partition coefficient, we applied the proposed Bayesian NCA method to 1,000 sets of simulated data with serial sacrifice design, and compared the obtained results with nominal values of the parameters. The experiment was simulated in R (Version 2.12.0) (22) and two scenarios were investigated: animals with tissue-compartment efflux transporter activity and animals without tissue-compartment efflux transporter activity. Sampling from 28 animals was simulated at 7 arbitrary time points (4 animals per time point) following a serial sacrifice design. The time points were set to be 0.5, 1, 2, 4, 8, 16, 24 h after the dose. A two-compartment PK model consisting of the plasma compartment and the tissue compartment was assumed (Fig. 2) . A single i.v. bolus dose of 1,000 units was given to the plasma compartment at time zero. Arbitrary PK parameters were defined in Table I 
CASE STUDY
The Bayesian method was applied to and evaluated in a realworld animal experiment. Briefly, brain and plasma levels of cediranib were determined following intravenous injection into wild-type (WT), P-glycoprotein (P-gp) gene-knockout (PgpKO or Mdr1a/b (-/-)), breast cancer resistance protein (BCRP) gene-knockout (BCRPKO or Bcrp1 (-/-)), and P-gp and BCRP triple gene-knockout (TKO or Mdr1a/b (-/-) Bcrp1 (-/-)) mice (23) . In this experiment, cediranib concentrations were assumed to be normally distributed. In order to explore whether the absence of P-gp or BCRP changes the bloodbrain barrier transport of cediranib, the brain-to-plasma partition coefficient (i.e., and 95% confidence intervals. In order to evaluate the performance of Bayesian method and compare it with the BailerSatterthwaite method, the posterior medians and 95% Bayesian credible intervals of the plasma and brain AUC 0 t were also computed and compared with the estimators obtained with Phoenix WinNonlin® 6.1 (Mountain View, CA) utilizing the Bailer-Satterthwaite method (14, 24) .
RESULTS

Simulation with Serial Sacrifice Design
Standard convergence diagnostics described in the "Method" section did not reveal significant MCMC convergence issues. BAV and WAV had little impact on the estimation bias under the serial sacrifice design. The proportions of simulations in which the true population mean was covered by the 95% credible interval are also shown in Table II . At all tested levels of variability, the Bayesian 95% credible interval had a good coverage rate (above 99%) of the true population mean.
Based on the simulation of extreme-case scenarios that either excluded the tissue efflux transporter activity or included a transporter with high activity, the Bayesian approach was able to adequately handle the parameters AUC 0,pl ∞ , AUC 0,br (Table II) .
Case Study
The Bayesian NCA approach has been applied to the brain distribution study of cediranib in wild-type and gene-knockout mice of brain efflux transporters, such as P-gp and BCRP; see more details in our experimental work (23) . The aim of the animal pharmacokinetic study was to compare the cediranib (-/-) Bcrp1(-/-) mice were also shown in the kernel density plots (Fig. 4) . The results confirmed the hypothesis that P-gp might play a predominant role in excluding cediranib out of the brain, based on the fact that the cediranib DTI in the Mdr1a/b(-/-) and were also slightly wider than the 95% confidence intervals obtained with jackknife resampling. The precision of Bayesian credible intervals for the estimated plasma and brain AU C t 0 was compared to the classic Bailer-type confidence intervals. Table IV shows that the Bayesian posterior medians of AUC 0 t in those mice groups were very close to the means (differences <15%) estimated by the Bailer-Satterthwaite method with the Bayesian 95% credible interval coverage similar to the 95% Bailer-type confidence intervals.
DISCUSSION
In a serial sacrifice tissue penetration study, assessing the estimation precision of AUC-based parameters such as partition coefficient and DTI is often desired. Since the plasma and tissue concentrations at the same time point are usually measured in the same animal, the correlation between the plasma and tissue concentrations may not be ignored. The biggest advantage of our proposed Bayesian NCA approach over most commonly used Bailer-type methods is its capability in evaluating the precision of AUC-based parameters of interest in a serial sacrifice design based on their posterior distributions. Unlike other approaches, this approach also inherently takes into account the correlation between tissue and plasma when calculating the plasma and tissue AUC. Our approach does not rely on any compartmental assumption but the first-order kinetics assumption of the terminal elimination phase. The simulation and case study in the model assumed linear distributional kinetics, i.e. , no saturation of the efflux clearance processes. However, the data analysis method to determine the statistical differences in the
would still be valid in the case of saturation of efflux, however the inference as to why the AUC ratios differ may be affected.
Bayesian credible intervals allow direct probability statements on the uncertainty of a parameter estimate (25) . It has been shown that the posterior median is a robust estimator for data with non-symmetric distributions, such as multimodal or skewed distributions (26) . Since the elimination phase rate constant was determined based on the assumption that terminal phase concentration data follow the log-normal distribution, the tail behavior of the non-symmetric distribution may affect the simulation-based sampling. That was the reason why the posterior median was used as a preferred estimator, along with the credible interval.
The performance of the Bayesian approach for AUC 0,pl ∞ , (15) . Although in the Bayesian approach, the observed data at the last sampling time were used in determination of posterior distributions of both C t and λ z , the samplings of λ z and C t were separated. Hence, it was anticipated that the Bayesian credible intervals are wider than the Yuan's confidence intervals. It is also not surprising that the jackknife confidence intervals were also narrower than the Bayesian credible intervals when the sample size is extremely small (e.g. , in our case, only four replicates at each time point). However, this derived jackknife intervals might not be reliable. As Efron points out, resampling intervals are not exact and may sometimes be vulnerable in small-sample situations (20) . In contrast, Bayesian approach in nature can avoid the dilemma of frequentist point estimation caused by the small sample size. The posterior distributions of the parameters of interest depend on both prior settings and study data, and small sample size is usually not an issue in Bayesian analysis. As such, our proposed approach is robust and adequate in the case study. Moreover, our approach considers the brain and plasma data correlation in model setting, which is another big advantage over the other methods. Although resampling maintains the data correlation between tissue and plasma within same animals, the AUC calculation based on resampling approaches is still unable to account for the tissue-and-plasma correlation, since presumably, the tissue and plasma AUCs are calculated independently. In parallel, the point estimates and the Bailer-type confidence intervals for the AU C t 0 s were compared to the Bayesian posterior medians and credible intervals in the case study. The purpose of the comparison was simply to show that the noninformative Bayesian method produced physiologically reasonable parameter estimations. Since the way Bayesian approach determines the terminal elimination phase was slightly different from Phoenix WinNonlin®, AUC 0 ∞ was not selected as a parameter to compare with the Phoenix WinNonlin® calculation results. Phoenix WinNonlin® calculates the terminal phase rate constant by repeating regressions using the last three points then the last four points, last five, etc. , until obtaining the best linear fit (27) . But the current study used only the last three time points with non-zero concentrations for the purpose of computation simplicity. Instead of AU C One criticism on the application of the Bayesian method is that the setting of the prior distribution is subjective and different priors may yield different posterior results. But the use of non-informative priors (e.g. , the uniform prior for logconcentration means) in this work can make this "subjectivity" minimal. Furthermore, incorporation of informative priors under some circumstances may be very helpful to investigate parameters. The Bayesian approach provides a flexible and powerful tool to borrow strength from other studies.
In the present simulation, the error at each sampling time was assumed to follow a log-normal distribution (proportional to the mean value of concentrations). Thus, the concentration data were log-transformed and the entire analysis was done on a log-scale. In the animal study, the normal likelihood worked adequately well and no significant difference between the normal likelihood and the log-normal likelihood was in that case. Other appropriate assumptions of likelihood and priors are worth exploring in further studies. However, when prior knowledge is available, it is strongly recommended to incorporate informative priors into the Bayesian approach. This will help narrow down the credible intervals of the Bayesian estimate and generate a more reliable posterior distribution. Another disadvantage of the Bayesian NCA approach is that it requires knowledge of Bayesian statistics and that the programming may be difficult to a non-statistician. The OpenBUGS code used in this analysis is included in the Supplementary Material.
CONCLUSION
Our proposed Bayesian approach provides a useful tool for variance estimation of the AUC 0 ∞ , the tissue-to-plasma ratio of AUC 0 ∞ , and the DTI, following destructive sampling. Posterior distribution of other NCA parameters could be obtained in likewise fashion. When prior knowledge is available, it is strongly recommended to incorporate informative priors into the Bayesian approach, in order to obtain a more reliable posterior estimation.
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